Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Yau, T.Merle, P.Rimassa, L.Ryoo, B-Y.Cicin, I.Harris, W. P.Banu, E.2024-06-122024-06-1220180923-75341569-8041https://hdl.handle.net/20.500.14551/26820European-Society-for-Medical-Oncology Asia Congress -- NOV 23-25, 2018 -- Singapore, SINGAPORE[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)Conference Object29Q1WOS:000458082200256